Carmat: break-even point targeted for 2027
After resuming its commercial operations, the Aeson artificial heart designer is continuing to set up new hospitals, with a target of 30 operational centers in Europe, mainly in Germany and Italy, by the end of 2023.
The ramp-up in production will be gradual, and should enable the production of over 100 artificial hearts by 2023. On this basis, Carmat anticipates sales of 10 to 13 million euros this year.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction